Investor relations
Biocompatibles is committed to delivering shareholder value by:
- developing and commercialising a range of products to treat various
cancer indications so as to improve the survival chances and quality of
life of cancer patients - developing products for growing markets and adhering to aggressive
timelines - responsibly managing the Company's financial resources
Following the sales of the contact lens and cardiovascular stent businesses in 2002, Biocompatibles has returned £123m of capital to shareholders.